Apparently: Stains ==> less cholesterol ==> less pre-vitamin D ==> less vitamin D from sun
- Short comment about stains and vitamin by Dr who wrote book about Statin Problems
- Dr. Eades on Statins increase vitamin D in blood in 2007
- Do Statin Drugs Cause Vitamin D Deficiency? - Jan 2010
- 1% to 5% of statin users get muscle pain - perhaps associated with depletion of vitamin D
See also VitaminDWiki
- Statins with low vitamin D increased chance of musculoskeletal pain by 2X – Jan 2015 < 15 ng
- Theories on the interaction between statins and vitamin D – 2012
- Rosuvastatin given for renal problem resulted in increased vitamin D levels – RCT Dec 2012
- Statin pain associated with 10 ng less vitamin D – meta-analysis Oct 2014
- Off topic: US and NZ permit drug advertising on TV, none permit tobacco advertising
- The statin Crestor dramatically increases levels of vitamin D in the blood – Jan 2012
- One statin decreased vitamin D levels but the other did not – March 2010
- Statin-induced Myalgias corrected with 100,000 weekly Vitamin D
- Statins associated with 14X increase in Polymyalgia Rheumatica (a new disease) – Aug 2012
- Click here to download 1 page PDF Sept 2009
- Not all statins increase vitamin D levels – Dec 2010
- Cholesterol and vitamin D
- Statin pain eliminated by taking 50,000 IU vitamin D weekly – July 2011
- Statin use increased probability of diabetes by 48 percent – perhaps via vitamin D Jan 2012
approximately 1 in every 4 adult Americans over 45 currently using statins to "prevent heart disease."
- Overview Cardiovascular and Vitamin D
- Breast cancer 2X more likely if have taken statins for 10 years – July 2013
- If you must take statins and want to avoid hardening of arteries, take vitamin K2 – RCT May 2015
- The statin Crestor dramatically increases levels of vitamin D in the blood – Jan 2012
Statin intolerance reduced as level of vitamin D is raised - July 2015
about 53% no longer statin intolerant if > 30ng of vitamin D
about 90% no longer statin intolerant if 54 ng of vitamin D
Download a letter to the editor from VitaminDWiki
Statins and Vitamin D in PubMed 225 items July 2016: examples follow:
- Is there really a relationship between serum vitamin D (25OHD) levels and the musculoskeletal pain associated with statin intake? A systematic review. April 2016 full free text
- Safety of 50,000-100,000 Units of Vitamin D3/Week in Vitamin D-Deficient, Hypercholesterolemic Patients with Reversible Statin Intolerance. March 2016 full free text
- Simvastatin and vitamin D for migraine prevention: A randomized, controlled trial. Dec 2015
- Statin Intolerance Because of Myalgia, Myositis, Myopathy, or Myonecrosis Can in Most Cases be Safely Resolved by Vitamin D Supplementation. March 2015 full free text
- Do women with statin-related myalgias have low vitamin D levels? Sept 2015 full free text
- Low plasma vitamin D levels and muscle-related adverse effects in statin users.Jan 2014 full free text
- The association between drugs frequently used by the elderly and vitamin D blood levels: a review of observational and experimental studies.Feb 2014
- Vitamin D3 effects on lipids differ in statin and non-statin-treated humans: superiority of free 25-OH D levels in detecting relationships Sept 2013
- Effect of simvastatin/ezetimibe 10/10 mg versus simvastatin 40 mg on serum vitamin D levels. May 2013
- Cardiovascular disease, statins and vitamin D. Feb 2012
- Possible mechanisms of interaction between statins and vitamin D May 2012
- Vitamin D deficiency, myositis-myalgia, and reversible statin intolerance. - July 2011
- Resolution of statin-induced myalgias by correcting vitamin D deficiency - May 2011
Do statins increase the level of vitamin D in the blood in the short term?
Question: Is this a direct effect, or is it due to statins reducing cholesterol, which is needed to produce vitamin D from the skin, but cholesterol is not needed if the vitamin D is taken as a supplement
Some people appear to think that vitamin D could serve the same function as statins at much lower cost and much lower risk
Note: one statin is the top selling US prescription drug - with more sales than the next two top-selling drugs
See also Web
- New York Times Article March 2012
About 1 in 200 on statins get diabetes
about 4 in 200 on statins do not get heart attack (if not had one before)
with 200 million taking statins in the US this amounts to 200,000 more people getting diabetes
- New statin guidelines: Everyone 40 and older should be considered for the drug therapy Nov 2016
The U.S. Preventive Services Task Force as reported by Washington Post
"The new guidelines, published in JAMA, suggests that people ages 40 to 75 who have one or more risk factors — such as high cholesterol, high blood pressure, diabetes or smoking that put them at a 10 percent or greater risk of having a heart attack or stroke in the next 10 years — should be on statins"
- FDA warning Feb 2012 Statins associated with"
Diabetes, *Muscle loss, *Memory loss
- Vascular Calcification Is Increased With Statin Use (VADT)
- Consumer Alert: 300+ Health Problems Linked To Statin Drugs Green Medical Information April 2012
- Do YOU Take Any of These 11 Dangerous Cholesterol Drugs? Mercola Aug 2012
over 900 studies proving adverse effects of statins
If You Take Statins, You MUST Take CoQ10
appropriate sun exposure normalizes your cholesterol levels and prevents heart disease
- The Many Health Benefits of Coenzyme Q10 and Ubiquinol Mercola June 2016
Some people do not have the gene which turns CoQ10 into Ubiquinol - interview with transcript
- Enhancement of vitamin D levels by statins Endocine conference June 2013
Patients who were taking statins were significantly more likely to have vitamin D levels at or above 30ng/ml (X2=5.5, p=0.02) than patients not on a statin
- Low vitamin D levels associated with statin induced muscle pain Vitamin D Council] March 2013
PLOS ONE free full text study; 21% more likely if low vitamin D
- Cholesterol drug users may use pills as a license to overeat April 2014
US statin users were eating about the same number of calories as non-users by 2009-2010.
- Statins: proven and associated harms May 2014 details, with RCT references
- Vitamin D status modifies the association between statin use and musculoskeletal pain: a population based study Jan 2015
2X more likely to have pain with statin if vitamin D <15 ng
- Statins May Dampen Response to Flu Vaccine
New York Times Nov 2015 - no mention of vitamin D
- A Systematic Review and Meta-analysis of 7 Studies with 2416 Patients 2014
statin-induced myalgia associated with -9.4 ng less vitamin D (7 studies, 2400 people - see table below
- Statins & Muscle Pain Dean - April, 2016
Comment on Medscape article on Statins
75% of those over 50 years old will be on statins!
10–20% have reported muscle-related side effects – pain and/or weakness
She recommends Magnesiun
See also Vitamin D Council behind a paywall
- Statins and heart health: Is vitamin D the missing link? April 2013 -
- Did you know: Statins raise vitamin D levels
. .market for statins nearly tripled when the National Cholesterol Education Program (NCEP) revised its guidelines to recommend statins as primary prevention.
Lancet had an article about the recommendation: Are lipid-lowering guidelines evidence-based?” Lancet 369 (9557)
8 of the 9 doctors on the NCEP panel were discovered to have been paid by statin manufacturers
7 out of 8 studies later found that Statins raised levels of vitamin D
- 30% fewer headaches if take statins Jan 2015
VitaminDWiki expects that Vitamin K2 could decrease the above side effects of statins
Rosuvastatin is a statin which increased vitamin D levels by 2.8X – Aug 2010
The JUPITER lipid lowering trial and vitamin D, Is there a connection?
William R Ware
Faculty of Science (Emeritus); University of Western Ontario; London, ON CA
Corresponding author. Correspondence to: William R. Ware; Email: warewr at rogers.com
Received May 6, 2010; Accepted August 3, 2010.
Dermatoendocrinol. 2010 Apr-Dec; 2(2): 50–54. doi: 10.4161/derm.2.2.13235
There is growing evidence that vitamin D deficiency significantly increases the risk of adverse cardiovascular events and that a vitamin D status representing sufficiency or optimum is protective. Unfortunately, in clinical trials that address interventions for reducing risk of adverse cardiovascular events, vitamin D status is not generally measured. Failure to do this has now assumed greater importance with the report of a study that found rosuvastatin at doses at the level used in a recent large randomized lipid lowering trial (JUPITER) had a large and significant impact on vitamin D levels as measured by the metabolite 25-hydroxyvitamin D. The statin alone appears to have increased this marker such that the participants on average went from deficient to sufficient in two months. The difference in cardiovascular risk between those deficient and sufficient in vitamin D in observational studies was similar to the risk reduction found in JUPITER.
Thus it appears that this pleiotropic effect of rosuvastatin may be responsible for part of its unusual effectiveness in reducing the risk of various cardiovascular endpoints found in JUPITER and calls into question the interpretation based only on LDL cholesterol and CRP changes. In addition, vitamin D status is a cardiovascular risk factor which up until now has not been considered in adjusting study results or in multivariate analysis, and even statistical analysis using only baseline values may be inadequate.
Text from the PDF
Rosuvastatin was given in doses of 10–20 mg/day and mean LDL levels decreased from 174 to 100 mg/dL.
At baseline the group had a mean level of 25(OH)D of 14 ng/mL which after 8 weeks of treatment increased to 36.3 ng/mL
PDF is attached at the bottom of this page
Benefits of Chocolate on the heart and all cause mortality (vs statins)
Green Med Info April 2012
Great many health benefits of chocolate documented -
Regarding just the heart: Chocolate appears to be better than statins.
Hypothesis of how statins can increase vitamin D blood levels, yet cause problems associated with vitamin D deficiency
Statins could decrease either the production or use of active vitamin D, that is, the form which is actually used in the body.
- suggested by Judy, Aug 2012
Simvastatin/Ezetimibe 10/10 mg increased Vitamin D levels 37%
Effect of Simvastatin/Ezetimibe 10/10 mg Versus Simvastatin 40 mg on Serum Vitamin D Levels.
J Cardiovasc Pharmacol Ther. 2013 Jan 2.
Liberopoulos EN, Makariou SE, Moutzouri E, Kostapanos MS, Challa A, Elisaf M.
Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.
Backround:Low levels of 25-hydroxyvitamin D (25(OH)VitD) have been recognized as an emerging cardiovascular disease (CVD) risk factor. Statins are reported to increase 25(OH)VitD concentration. Animal studies suggest that ezetimibe is a moderate inhibitor of intestinal 25(OH)VitD absorption, but its effect in humans is unknown.Aim:To investigate whether combined treatment with simvastatin/ezetimibe 10/10 mg would increase 25(OH)VitD levels compared to simvastatin 40 mg monotherapy in patients with primary hypercholesterolemia.
In a Prospective Randomized Open-label Blinded End point study, 50 patients with primary hypercholesterolemia received either simvastatin/ezetimibe 10/10 mg (n = 25) or simvastatin 40 mg (n = 25) daily for 3 months. The primary end point was between-group difference in the change of serum 25(OH)VitD levels.
Simvastatin/ezetimibe 10/10 mg was associated with a 36.7% increase in 25(OH)VitD serum levels (from 6.8 to 9.3 ng/mL, P = .000), while simvastatin 40 mg was associated with a 79.1% increase (from 6.7 to 12.0 ng/mL, P = .008). The increase in 25(OH)VitD levels in the simvastatin 40 mg group was significantly greater compared to that in the simvastatin/ezetimibe 10/10 mg group (P = .04). Both groups exhibited similar reductions in low-density lipoprotein cholesterol (LDL-C) levels.
For similar LDL-C lowering simvastatin 40 mg is associated with greater increase in 25(OH)VitD compared to simvastatin/ezetimibe 10/10 mg.
Whether this difference is relevant in terms of CVD risk reduction is unknown.
A New Women’s Issue: Statins NYT May 2014
- If you’re going to tell a healthy person to take a medicine every day for the rest of their life, you should have really good data that it’s going to make them better off,
- statins didn’t prevent healthy women from having their first heart attacks and didn’t save lives.
- Women who are healthy derive no benefit from statins, and even those women who have established heart disease derive only half the benefit men do.
- The drugs have long been known to cause muscle pain in some people and, more rarely, liver and kidney damage, as well as cognitive side effects like memory loss and confusion
- postmenopausal women who took part in the Women’s Health Initiative were much more likely to develop diabetes if they took statins, and diabetes itself increases the risk of heart disease considerably.
Summary by VitaminDWiki: No proof that statins helps healthy women, but there is proof that statins harms them
Statin Health problems - GreenMedInfo
- Feb 2015 (nothing about vitamin D)
- Cracking the Cholesterol Myth: How Statins Harm The Body and Mind
A new study finds the chemical war against cholesterol using statin drugs was justified through statistical deception and the cover up of over 300 adverse health effects documented in the biomedical literature
|Muscle damage 80 studies||Nerve damage 54 studies||+Liver damage 32 studies|
|Endocrine disruption: 16 studies||Cancer-promoting: 9 studies||Diabetes-promoting: 8 studies|
|Cardiovascular-damaging: 15 studies||Birth defect causing 11 studies|
- The JUPITER trial of Crestor vs placebo resulted in increased fatal heart attacks in the treatment group which were obscured by combing fatal and nonfatal infarctions.
- The HPS study has 26% drop out rate prior to the beginning of the trial, so that those with significant side effects were functionally excluded from the study.
- In at least four trials, statistically significant increases in cancer incidence was found, and handily dismissed by all authors as insignificant because they claimed "no known potential biological basis" is known.
- A low serum cholesterol level has also been found to serve as a biological marker of major depression and suicidal behavior,
suicidal ideation among adults with mood disorders was more than 2.5-times greater in those taking statins
- "So, the next time you hear of a doctor recommending a cholesterol-lowering intervention, tell him you'll take that 1% risk and spare yourself cancer, cognitive dysfunction, myopathy, and diabetes"
Aug 2016 Video
If you really must take statins and they cause pain, vitamin D will relieve the pain
Statin Intolerance Because of Myalgia, Myositis, Myopathy, or Myonecrosis Can in Most Cases be Safely Resolved by Vitamin D Supplementation March 2015
50,000 or 100,000 IU of vitamin D2 per week relieved statin pain
Download the PDF from VitaminDWiki
- ConsumerLabs has a nice summary of this as well as many other vitamin D studies behind a subscription paywall
Thier paywall is very much worth the price. They review a huge number of supplements
I have subscribed for over a decade
80% of the people who should take statins have decided not to (TOO many side effects?) - May 2015
- Eight in 10 Primary-Prevention Patients Skip Statins, Dutch Study Finds Medscape
70,000 participants in the LifeLines cohort study
Conclusion of the report - doctors need to insist that the patients actually take the statins
Statins associated with low vitamin D - Dec 2015
Statin therapy and Vitamin D
Int J Basic Clin Pharmacol. 2015; 4(6): 1113-1117doi: 10.18203/2319-2003.ijbcp20151342
Arunkumar Radhakrishnan, A. Ruckmani, M. Abishek, S. Govindaraju.
Background: Statins are well-known drugs used in dyslipidemia and cardiac disorders since several years. Recently, it has been reported that long-term use of statins reduce serum vitamin D level. When statins are administered to patients with low vitamin D more muscular side effects have been reported. On the contrary, a few studies report that statins might increase vitamin D level competing with its metabolism. Hence, this study was conducted to evaluate the association between statins and vitamin D.
Methods: 125 participants who fulfilled the selection criteria were enrolled in the study. 65 subjects belonged to control group and 60, statin group. The blood sample was collected for Vitamin D estimation. The results were correlated with a demographic profile, nature of statin and the muscular side effects and compared with control group.
Results: The mean vitamin D level in statin group was 15.82 ng/ml±11.51 and 20.57 ng/ml±7.007 in the control group. The difference was found to be statistically significant. 13.85% in the control group and 10% in statin group had sufficient vitamin D level. 18.33% and 36.92 % had insufficient levels and 71.67% and 49.23% had a deficiency in the statin and control groups respectively. Myalgia was reported by 30 among 60 subjects (50%) in statin group and 5 among 65 subjects (7.69%) in the control group.
Conclusion: The present study has shown that statin therapy is associated with low vitamin D level and that this could contribute to the increased incidence of myalgia in the statin group.
Statin intolerance ==> statin tolerance after add lots of vitamin D - March 2016
ID: 86: SAFETY OF 50,000-100,000 UNITS OF VITAMIN D3 PER WEEK IN VITAMIN D DEFICIENT, HYPERCHOLESTEROLEMIC PATIENTS, WITH STATIN INTOLERANCE
Journal of Investigative Medicine
V Jetty, G Duhon, P Shah, M Prince, K Lee, M Goldenberg, A Kumar, CJ Glueck, P Wang
DOI: 10.1136/jim-2016-000120.39 Published 22 March 2016
Background In ∼85–90% of statin intolerant patients, vitamin D deficiency (serum 25 (OH) D <32 ng/ml) is a reversible cause of statin intolerance, usually requiring 50,000 to 100,000 units of vitamin D/week continuously to normalize serum vitamin D, and thus successfully allow reinstitution of statins which previously could not be tolerated because of myalgia-myositis.
Specific Aim In 274 statin intolerant patients, all with low entry serum vitamin D (<32 ng/ml, median 21 ng/ml), we assessed safety and efficacy of vitamin D supplementation (50,000–100,000 units/week) over treatment periods of 3 months (n=274), 3 and 6 months (n=161), 3, 6, and 9 months (n=58), and 3, 6, 9, and 12 months (n=22).
Results In the 385 patients with 3 month follow-up, taking mean 61,000 and median 50,000 IU of vitamin D3/week, median serum vitamin D rose from 20 to 42 ng/ml (p<0.0001); vitamin D became high (>100 ng/ml) but not toxic-high (>150 ng/ml) in 4 patients (1.0%) (101, 102, 106, 138 ng/ml). Median serum calcium was unchanged from entry (9.6 mg/dl) to 9.6 at 3 months. On vitamin D supplementation, the trend of change in serum calcium from normal-to-high or from high-to-normal did not significantly differ (McNemar S=1.0, p=0.32), and there was no significant trend in change of the calculated glomerular filtration rate (eGFR) from entry to follow-up (McNemar S=2.6, p=0.11).
In the 161 patients with 3 and 6 month follow-up, taking mean 67,000 and median 50,000 IU of vitamin D3/week, median entry serum vitamin D rose from 21 to 42 to 44 ng/ml (p<0.0001), serum vitamin D was high (>100 but <150 ng/ml) in 2 patients at 3 months (1.2%, 101, 102 mg/ml) and in 3 (1.9%) at 6 months (101, 140, 140 ng/ml). Median serum calcium was unchanged from entry (9.7 mg/dl), at 3 and 6 months (9.7, 9.6 mg/dl, p>0.05). On vitamin D supplementation, the change in serum calcium from normal-to-high or high-to-normal was no significant trend (McNemar S=0.7, p=0.41), and no trend in change of eGFR (McNemar S=1.3, p=0.26).
In the 58 patients with 3, 6, and 9 month follow-up on mean and median 71,000 and 100,000 IU of D3/week, median entry vitamin D rose from 20 to 37, 41, and 44 ng/ml (p<0.0001), with 1 (1.7%, 102 ng/ml), 2 (3.5%, 140, 140 ng/ml), and 0 (0%) patients high. Median serum calcium was unchanged from entry, median 9.7, 9.8, 9.6, and 9.6 mg/dl. On vitamin D supplementation, the trend of change in serum calcium from normal-to-high or high-to-normal was not significant (McNemar S=1.8, p=0.18), and no trend in change of eGFR (McNemar S=2, p=0.16).
In the 22 patients with follow-up at 3, 6, 9, and 12 months on mean and median 70,000 and 75,000 IU of D3/week, median serum vitamin D rose from 20 to 37, to 41, to 44, and to 43 ng/ml (p<0.0001), with 1 (5%, 102 ng/ml) high, 2 (9%, 140, 140) high, 0 (0%) high, and 1 (5%, 126 ng/ml) high. Serum calcium was unchanged, median at entry 9.6, and then at 3, 6, 9, and 12 months 9.7, 9.7, 9.5, and 9.7 mg/ml. At entry serum calcium was normal in 21, none high, and one became high at 12 month follow-up. The trend of change in eGFR was insignificant, McNemar S=1.0, p=0.32.
When serum D rose above 100 ng/ml in the few cases, as above, it fell into the normal range within 2 weeks by reducing the vitamin D dose by 50%.
Conclusions When 50,000–100,000 units of vitamin D/week are given to reverse statin intolerance in statin intolerant patients with low entry vitamin D (<32 ng/ml), it appears to be safe over up to 1 year follow-up, without toxic high serum vitamin D levels >150 ng/ml, and levels rarely >100 ng/ml, and without changes in serum calcium or eGFR.
- - - -
A study has the same conclusion later in 2016
Rechallenging Statin Therapy in Veterans With Statin-Induced Myopathy Post Vitamin D Replenishment
41% tolerated their previously failed statins after taking vitamin D; free PDF is online
This high dose of this statin (abstract does not say which) increased vitamin D levels, by 20% - April 2016
IMPACT OF HIGH-DOSE STATINS ON VITAMIN D LEVELS AND PLATELET FUNCTION IN PATIENTS WITH CORONARY ARTERY DISEASE
J Am Coll Cardiol. 2016;67(13_S):2349-2349. doi:10.1016/S0735-1097(16)32350-6
Monica Verdoia; Lucia Barbieri; Alon Schaffer; Paolo Marino; Harry Suryapranata; Giuseppe De Luca
Statins represent a pivotal treatment in coronary artery disease (CAD), offering “pleiotropic” benefits in cardiovascular risk far beyond the lipid-lowering action. Vitamin D has been suggested as a potential mediator of the anti-atherosclerotic and anti-thrombotic effects of statins. Aim of present study was to assess the impact of a high-intensity statin therapy on vitamin D levels and platelet function in patients with coronary artery disease.
Patients discharged on dual antiplatelet therapy and high-intensity statins after an acute coronary syndrome or elective PCI were scheduled for main chemistry and vitamin D levels assessment at 30-90 days post-discharge. Platelet function was assessed by Multiplate® (Roche Diagnostics AG).
Among 246 patients included, 142 were discharged on a new statin therapy or with an increase in previous dose (Inc-S), while 104 were already receiving a high-dose statin at admission, that remained unchanged (eq-S). Patients in the Inc-S group were younger (p=0.01), smokers (p<0.001), less often hypercholesterolemic (p=0.05), diabetic (p=0.03), with hypertension (p=0.02), or previous cardiovascular events (p<0.001), and more frequently admitted for acute coronary syndrome (p<0.001). Baseline vitamin D levels were similar in the 2 groups (p=0.30). A significant reduction in circulating low-density lipoprotein (LDL) cholesterol was observed in the Inc-S group. Vitamin D levels increased in the Inc-S patients but not in the eq-S group (delta-25OHD: 23.2±20.5% vs 3.1±4.7%, p=0.003), with a linear relationship between the magnitude of vitamin D elevation and the reduction of LDL cholesterol (r=-0.17, p=0.01). Platelet reactivity was significantly lower in the Inc-S patients, with different platelet activating stimuli (arachidonic acid, p=0.02, collagen, p=0.004, thrombin-activating peptide, p=0.07, ADP, p=0.002).
In patients with CAD, the addition of a high-intensity statin treatment is associated to a significant increase in vitamin D levels and lower platelet reactivity, potentially providing explanation of the “pleiotropic” benefits of statins therapy in cardiovascular disease.
Atorvastatin decreases D levels via CPY3A4; parvastatin increases D levels vai CYP27A1 - 2016
Those with Statin pain were 3 times more likely to have levels of low vitamin D – Nov 2016
Impact of Vitamin D Status on Statin-Induced Myopathy
J of Clinical and Translational Endocrinology DOI: http://dx.doi.org/10.1016/j.jcte.2016.11.002
Krista D. Riche, Justin Arnall, Kristin Rieser, Honey E. East, Daniel M. Riche
Download the PDF from VitaminDWiki
•Vitamin D status plays an important role in the consideration of statin-induced myopathy.
•Correction of vitamin D deficiency ( 20 ng/mL) can improve statin tolerance rates.
There is a multitude of evidence supporting the benefit of statin use in cardiovascular disease; however, statin-induced myopathy is a major reason for statin discontinuation and non-adherence. Vitamin D deficiency has been independently associated with muscle weakness and severe myopathy, and may be a confounder for statin-induced myopathies. Since there is no consensus on a treatment course of action for statin-induced myopathy, investigation into potential confounders to elucidate the dynamics of statin-induced myopathy is warranted.
A retrospective chart review was conducted on 105 patients in a cardiometabolic clinic with a vitamin D drawn from December 2006 to April 2008. Patients exposed to statins were divided into two groups: (1) patients with low vitamin D (<32 ng/mL) n=52 and (2) patients with a sufficient vitamin D level ( 32 ng/mL) n=32. Data were compared via t-tests or Fisher’s Exact, as appropriate.
There were 41 statin-specific myopathies amongst the 24 statin-intolerant patients. Low vitamin D was significantly associated with statin-induced myopathy (p=0.048). Following prescription vitamin D supplementation, statin tolerance rates were significantly higher in patients with a baseline vitamin D 20 ng/mL than those with a baseline vitamin D >20 ng/mL (90% vs 33%; p=0.036).
Vitamin D status may be considered a modifiable risk factor for muscle-related adverse effects of statins, and supplementation of vitamin D (particularly when 20 ng/mL) may improve statin tolerance.